The advent of CRISPR-Cas systems has ushered in a transformative era in biomedical research, particularly regarding complex diseases such as periodontal disease. This multifaceted condition is driven by a combination of microbial dysbiosis and host immune responses, leading to a progressive inflammatory state that can culminate in tooth loss if not managed effectively. Recent investigations have highlighted the potential of CRISPR technology to address these underlying causes by targeting specific microbial elements and modulating host responses. The integration of CRISPR-Cas systems into precision periodontal therapy not only promises a tailored approach to treatment but also raises pertinent questions regarding the ethical considerations and technical limitations associated with gene editing. Thus, this exploration aims to elucidate the intricate role of CRISPR-Cas systems in the pathogenesis of periodontal disease while also assessing their therapeutic potential and implications for future clinical applications.
16 October 2023 in European Journal of Hybrid Imaging
Background: Hepatic steatosis is the most common chronic hepatic disease. Imaging diagnosis of hepatic steatosis has been evaluated as an alternative to invasive histological diagnosis. Study aims: The study aimed to assess the effect of hepatic steatosis on Flourine-18 fluorodeoxyglucose (18F-FDG) uptakes in cancer patients. Patients and Methods: Blood samples were collected from 50 cancer patients and analyzed to calculate fatty liver index and Hepatic steatosis index (HIS). Hepatic steatosis examined using high-resolution ultrasound and positron emission tomography—computed tomography (PET-CT). Linear attenuation coefficient, standardized-uptake value (SUV) mean (SUV mean), and SUV maximum (SUVmax) were measured. Accordingly, patients were divided equally into non-fatty liver, and fatty liver groups. Results: A significant increase in SUVmax and SUV mean was observed in the fatty liver group more than in the non-fatty liver group. HSI significantly increased in the fatty liver group compared to the non-fatty liver group. Liver tissue uptake FDG was significantly correlated with HSI values. SUV max significantly correlated with body mass index (BMI) in the non-fatty group only. Conclusion: Hepatic changes in cancer patients affect the liver metabolic activity and thus the 18 F-FDG uptake. Therefore, further corrections should be considered when the liver is used as a comparator for PET-CT scans of cancer patients.